PROFOUND MEDICAL CORP. Finance Costs
PROFOUND MEDICAL CORP. (PROF) reported Finance Costs of $303.00 thousand for the 12-month period ending 2021-12-31, per its 40-F filed 2022-03-03.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:FinanceCosts · last filed 2022-03-03
CAD
| Period end | Finance Costs 12 month |
|---|---|
| 2019-12-31 | 711.59K CAD 40-F · filed 2020-03-03 |
| 2018-12-31 | 826.31K CAD 40-F · filed 2020-03-03 |
USD
| Period end | Finance Costs 12 month |
|---|---|
| 2021-12-31 | $303.00K 40-F · filed 2022-03-03 |
| 2020-12-31 | $2.71M 40-F · filed 2022-03-03 |
| 2019-12-31 | $171.00K 40-F · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |